Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729068 | 0.91 | OPRL1 (0.54) | EGLN1ALDH1A1OPRL1KMT2AUSP2 | |
| SCHEMBL3733515 | 0.90 | OPRL1 (0.54) | EGLN1ALDH1A1OPRL1PKMKMT2A | |
| SCHEMBL3731861 | 0.88 | OPRL1 (0.60) | ALDH1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL3730232 | 0.87 | HSD11B1 (0.50) | EGLN1OPRL1 | |
| SCHEMBL3738860 | 0.86 | OPRL1 (0.52) | EGLN1ALDH1A1OPRL1PKMKMT2A | |
| SCHEMBL3735311 | 0.82 | OPRL1 (0.43) | EGLN1OPRL1OPRM1OPRK1 | |
| SCHEMBL3729066 | 0.82 | OPRL1 (0.47) | EGLN1ALDH1A1OPRL1OPRM1OPRK1 | |
| SCHEMBL3739308 | 0.82 | OPRL1 (0.50) | EGLN1ALDH1A1OPRL1PKMCYP2D6 | |
| SCHEMBL3734017 | 0.81 | LMNA (0.44) | EGLN1ALDH1A1OPRL1KMT2AOPRM1 | |
| SCHEMBL3735041 | 0.81 | OPRL1 (0.55) | EGLN1ALDH1A1OPRL1PKMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | EGLN1 811/4885ALDH1A1 2486/4885OPRL1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.